A detailed history of Northern Trust Corp transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,535,856 shares of BLUE stock, worth $552,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,535,856
Previous 1,615,321 4.92%
Holding current value
$552,908
Previous $1.58 Million 49.59%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$0.47 - $1.35 $37,348 - $107,277
-79,465 Reduced 4.92%
1,535,856 $798,000
Q2 2024

Aug 14, 2024

SELL
$0.85 - $1.26 $5,022 - $7,445
-5,909 Reduced 0.36%
1,615,321 $1.58 Million
Q1 2024

May 14, 2024

BUY
$0.91 - $1.75 $565,102 - $1.09 Million
620,992 Added 62.08%
1,621,230 $2.08 Million
Q4 2023

Feb 13, 2024

SELL
$1.32 - $4.83 $173,944 - $636,478
-131,776 Reduced 11.64%
1,000,238 $1.38 Million
Q3 2023

Nov 13, 2023

BUY
$3.02 - $4.05 $25,739 - $34,518
8,523 Added 0.76%
1,132,014 $3.44 Million
Q2 2023

Aug 11, 2023

BUY
$2.79 - $5.03 $560,039 - $1.01 Million
200,731 Added 21.75%
1,123,491 $3.7 Million
Q1 2023

May 15, 2023

BUY
$3.14 - $8.22 $445,826 - $1.17 Million
141,983 Added 18.18%
922,760 $2.93 Million
Q4 2022

Feb 13, 2023

BUY
$5.77 - $8.49 $577,334 - $849,492
100,058 Added 14.7%
780,777 $5.4 Million
Q3 2022

Nov 14, 2022

BUY
$3.75 - $7.39 $178,068 - $350,914
47,485 Added 7.5%
680,719 $4.31 Million
Q2 2022

Aug 12, 2022

SELL
$2.94 - $5.23 $202,854 - $360,859
-68,998 Reduced 9.83%
633,234 $2.62 Million
Q1 2022

May 13, 2022

SELL
$4.07 - $10.6 $72,254 - $188,181
-17,753 Reduced 2.47%
702,232 $3.41 Million
Q4 2021

Feb 08, 2022

BUY
$8.96 - $16.31 $21,038 - $38,295
2,348 Added 0.33%
719,985 $7.19 Million
Q3 2021

Nov 15, 2021

SELL
$11.24 - $21.0 $199,678 - $373,065
-17,765 Reduced 2.42%
717,637 $13.7 Million
Q2 2021

Aug 13, 2021

BUY
$18.04 - $22.09 $7.57 Million - $9.26 Million
419,380 Added 132.71%
735,402 $23.5 Million
Q1 2021

May 12, 2021

BUY
$16.59 - $33.89 $41,591 - $84,962
2,507 Added 0.8%
316,022 $9.53 Million
Q4 2020

Feb 11, 2021

SELL
$27.5 - $37.92 $128,617 - $177,351
-4,677 Reduced 1.47%
313,515 $13.6 Million
Q3 2020

Nov 16, 2020

SELL
$34.44 - $43.75 $106,901 - $135,800
-3,104 Reduced 0.97%
318,192 $17.2 Million
Q2 2020

Aug 14, 2020

BUY
$27.12 - $45.97 $1.24 Million - $2.1 Million
45,733 Added 16.6%
321,296 $19.6 Million
Q1 2020

May 14, 2020

BUY
$26.16 - $63.5 $477,027 - $1.16 Million
18,235 Added 7.09%
275,563 $12.7 Million
Q4 2019

Feb 14, 2020

BUY
$46.96 - $61.67 $209,864 - $275,603
4,469 Added 1.77%
257,328 $22.6 Million
Q3 2019

Nov 13, 2019

SELL
$59.47 - $93.1 $789,880 - $1.24 Million
-13,282 Reduced 4.99%
252,859 $23.2 Million
Q2 2019

Aug 13, 2019

BUY
$75.84 - $105.21 $81,755 - $113,416
1,078 Added 0.41%
266,141 $33.9 Million
Q1 2019

May 13, 2019

BUY
$64.44 - $104.11 $431,941 - $697,849
6,703 Added 2.59%
265,063 $41.7 Million
Q4 2018

Feb 12, 2019

BUY
$59.1 - $93.26 $138,116 - $217,948
2,337 Added 0.91%
258,360 $25.6 Million
Q3 2018

Nov 14, 2018

BUY
$88.86 - $117.49 $1.34 Million - $1.77 Million
15,087 Added 6.26%
256,023 $37.4 Million
Q2 2018

Sep 18, 2018

SELL
$99.64 - $127.59 $320,641 - $410,584
-3,218 Reduced 1.32%
240,936 $37.8 Million
Q2 2018

Aug 14, 2018

SELL
$99.64 - $127.59 $34.7 Million - $44.4 Million
-348,044 Reduced 58.77%
244,154 $38.3 Million
Q1 2018

May 09, 2018

BUY
$105.8 - $150.94 $279,735 - $399,085
2,644 Added 0.45%
592,198 $101 Million
Q4 2017

Feb 14, 2018

BUY
$81.25 - $130.7 $2.43 Million - $3.91 Million
29,911 Added 5.34%
589,554 $105 Million
Q3 2017

Nov 13, 2017

BUY
$57.74 - $91.42 $32.3 Million - $51.2 Million
559,643
559,643 $76.9 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $27.8M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.